Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that new information on AVR118 has been accepted for publication in the 2007 Proceedings of the American Society of Clinical Oncology (ASCO) Abstract publication. This publication will be distributed to the nearly 25,000 oncology practioners who will be attending this year’s meeting in Chicago on June 1-5.
Based on recent work conducted by ADVR, new insight has been made regarding the chemical composition of AVR118. As a result of these findings, clinicians will have a better understanding of how AVR118 exerts its clinical effects, whether it is administered topically or systemically. Additionally, this work may provide clues on how new formulations of AVR118 may be produced with greater activity in a variety of different clinical applications.
“Based on our new understanding of how AVR118 exerts its cytoprotective effects, we are in a much better position to understand how it might be used more effectively to stimulate appetite, improve fatigue, and assist in rapidly reversing the toxic side-effects of chemo, radiation and possibly even interferon therapies. We now have evidence that it binds to adenosine receptors in-vitro and increases cAMP release in several different cell lines. Its anti-anorexic activity may involve targeted receptor binding in the gut and in the functional pathway of orexin A. AVR118 has also shown a 20% enhancement of epitheliazation when compared to saline controls in a controlled porcine wound healing model” says, Dr. J. T. D'Olimpio, author of the abstract.
“Based on our improved understanding of the composition of AVR118, we are in a much better position to predict the potential clinical indications for our product,” says Stephen M. Elliston, CEO and President of Advanced Viral Research Corp. “Up until now there has been a major unmet need for new non-toxic orexigenic and cytoprotective agents that can ameliorate some of the intractable symptoms associated with cancer related cachexia. Today, we are increasingly optimistic that AVR118 might provide a much needed alternative to existing therapies,” added Elliston. |
